{"entity":{"id":"paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021","kind":"paper","name":"CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma","aka":[],"tldr":"A second PD-1 antibody, camrelizumab, also lengthened progression-free survival when added to gemcitabine and cisplatin in metastatic nasopharyngeal cancer, confirming that chemo-immunotherapy is the new first-line standard.","summary":"Chinese multicentre randomised double-blind phase 3 trial of 263 patients with recurrent or metastatic nasopharyngeal carcinoma assigned to camrelizumab or placebo with gemcitabine and cisplatin, followed by maintenance.\n\nMedian progression-free survival was 9.7 months with camrelizumab against 6.9 months with placebo (hazard ratio 0.54), with a higher response rate; reactive cutaneous capillary endothelial proliferation, characteristic of camrelizumab, was common but mostly mild.","asOf":"2026-09-18","links":[{"label":"Lancet Oncol 2021","url":"https://doi.org/10.1016/S1470-2045(21)00302-8"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34174189/"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-nasopharyngeal-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["camrelizumab","gemcitabine-cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["captain-1st"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00302-8","pmid":"34174189","authors":"Yang Y, Qu S, Li J, et al.","paperType":"rct","findings":["Median progression-free survival 9.7 months with camrelizumab plus chemotherapy versus 6.9 months with chemotherapy alone; hazard ratio 0.54."],"whatItMeans":"Together with JUPITER-02 and RATIONALE-309, this trial made PD-1 blockade plus gemcitabine-cisplatin the first-line standard for metastatic nasopharyngeal carcinoma.","caveats":["Conducted entirely in China.","Overall survival data were immature at publication."],"changedPractice":true,"participants":263},"route":"/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/","neighbours":{"cancer":[{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"}],"trial":[{"id":"captain-1st","kind":"trial","name":"CAPTAIN-1st","route":"/trials/captain-1st/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}